<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158532</url>
  </required_header>
  <id_info>
    <org_study_id>Nitroglycerin on Occlusion</org_study_id>
    <nct_id>NCT03158532</nct_id>
  </id_info>
  <brief_title>Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin</brief_title>
  <acronym>Patens</acronym>
  <official_title>Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Cardiologia de Santa Catarina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Cardiologia de Santa Catarina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The radial approach for a coronary angiography has became popular in several centers because
      of its simplicity and fewer complications. The radial artery occlusion (RAO) is the main
      inconvenient and impose a limitation of future use of the radial artery as an access site for
      catheterization in the future. Several strategies have been used to decrease the incidence of
      RAO (heparin, patent hemostasis, etc). Nitrates in intra-arterial have been widely studied in
      prevention of this spasm. Current data show that nitroglycerin intra-arterial at the end of
      the procedure reduce the incidence of RAO. The hypothesis that use of nitroglycerin at the
      start of catheterization would have the same effect was not tested.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transradial access (TRA) has been increasingly adopted for diagnostic and interventional
      cardiovascular procedures in many centers worldwide. This is largely driven by the evidence
      supporting an unequivocal reduction in access site-related complications associated with TRA
      compared with transfemoral access, as well as reduction in cost and increased patient
      comfort. The radial artery occlusion (RAO) is the main inconvenient and impose a limitation
      of future use of the radial artery as an access site for catheterization in the future. RAO
      is the most commun complication of transradial access, and its incidence continues to reach
      up to 12%.

      Nitrates in intra-arterial have been widely studied in prevention of this spasm.
      Nitroglycerin binds to the surface of endothelial cells and undergoes two chemical reductions
      to form nitric oxide (NO). The nitric oxide then moves out of the endothelial cell and into
      an adjacent smooth muscle cell, where it promotes the formation of cyclic guanosine
      monophosphate (cGMP), which then promotes muscle relaxation. Current data show that
      nitroglycerin intra-arterial at the end of the procedure reduce the incidence of radial
      artery occlusion.

      A big sheath to artery size ratio could reduce the incidence of RAO, so the main objective of
      this study is to evaluate whether administration of nitroglycerin at the start of a
      transradial procedure may preserve the patency of the radial artery; as well, confirm if
      nitroglycerin administration just before sheet removal helps to keep the radial artery
      patency.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radial artery occlusion</measure>
    <time_frame>2 to 24 hours after procedure</time_frame>
    <description>Incidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular doppler ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late radial artery occlusion</measure>
    <time_frame>30 days after procedure</time_frame>
    <description>Incidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular doppler ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>up to 24 hours after procedure</time_frame>
    <description>Pain felt by the patient in the forearm, assessed using numeric pain rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasm (operator evaluation)</measure>
    <time_frame>Immediate</time_frame>
    <description>Catheter friction, as experienced by the operator (subjective measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>Immediate</time_frame>
    <description>Total duration of the procedure, from puncture to haemostatic dressing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation exposure</measure>
    <time_frame>Immediate</time_frame>
    <description>Total radiation used in the procedure</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2128</enrollment>
  <condition>Injury of Radial Artery</condition>
  <arm_group>
    <arm_group_label>Placebo I/Placebo II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitroglycerin I/Placebo II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo I /Nitroglycerin II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitroglycerin I /Nitroglycerin II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin I</intervention_name>
    <description>500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.</description>
    <arm_group_label>Nitroglycerin I/Placebo II</arm_group_label>
    <arm_group_label>Nitroglycerin I /Nitroglycerin II</arm_group_label>
    <other_name>Tridil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo I</intervention_name>
    <description>Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.</description>
    <arm_group_label>Placebo I/Placebo II</arm_group_label>
    <arm_group_label>Placebo I /Nitroglycerin II</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin II</intervention_name>
    <description>500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.</description>
    <arm_group_label>Placebo I /Nitroglycerin II</arm_group_label>
    <arm_group_label>Nitroglycerin I /Nitroglycerin II</arm_group_label>
    <other_name>Tridil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo II</intervention_name>
    <description>Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.</description>
    <arm_group_label>Placebo I/Placebo II</arm_group_label>
    <arm_group_label>Nitroglycerin I/Placebo II</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for cardiac catheterization;

          -  Suitable candidates for transradial approach;

          -  Use of 5 or 6 French sheath in the procedure;

          -  Signed informed consent.

        Exclusion Criteria:

          -  Unable to tolerate nitrates or known allergy to nitrates;

          -  Use of any nitrate, by any route of administration, up to 1 hour before the procedure;

          -  ST-segment elevation acute myocardial infarction patients during the first 12 hours of
             sympton onset;

          -  Intubated patients (on mechanical ventilation);

          -  Complications before or during procedure (cardiac arrest, pulmonary edema, cardiogenic
             shock, stroke);

          -  Prior inclusion in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto L da Silva, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Cardiologia de Santa Catarina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José R Costa Júnior, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto L da Silva, MD</last_name>
    <phone>+55 48 32719077</phone>
    <email>roberto.leo@ufsc.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto de Cardiologia do Distrito Federal</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <zip>70658-700</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luciano M Santos, MD</last_name>
      <phone>+55 61 3403-5400</phone>
    </contact>
    <investigator>
      <last_name>Luciano M Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Professor Polydoro Ernani de São Thiago</name>
      <address>
        <city>Florianópolis</city>
        <state>Santa Catarina</state>
        <zip>88036-800</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thaís RW da Silva, PhD</last_name>
      <phone>+55 48 37219100</phone>
    </contact>
    <investigator>
      <last_name>Thaís RW da Silva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto L da Silva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Cardiologia de Santa Catarina</name>
      <address>
        <city>São Jose</city>
        <state>SC</state>
        <zip>88000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto L da Silva, MD</last_name>
      <phone>55 48 32719077</phone>
      <email>roberto.leo@ufsc.br</email>
    </contact>
    <investigator>
      <last_name>Roberto L da Silva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade Santa Casa Misericórdia Marília</name>
      <address>
        <city>Marília</city>
        <state>São Paulo</state>
        <zip>17515-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro B Andrade, PhD</last_name>
      <phone>+55 14 3402-5555</phone>
    </contact>
    <investigator>
      <last_name>Pedro B Andrade, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto L da Silva, MD</last_name>
      <phone>+55 48 999099790</phone>
    </contact>
    <investigator>
      <last_name>José R Costa Júnior, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Cardiologia de Santa Catarina</investigator_affiliation>
    <investigator_full_name>Roberto Léo da Silva</investigator_full_name>
    <investigator_title>Intervencional cardiologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

